LYON, France--(BUSINESS WIRE)--ResMed, a pioneer and global leader in sleep and respiratory medicine, has announced the launch of its ResMed Air Solutions range, led by the intelligent, cloud-enabled AirCurve 10 CS PaceWave™ with AirView system. This is the first device to combine remote monitoring with ResMed’s innovative PaceWave™ Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy. Through a unique patented algorithm, PaceWaveTM MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing. This is especially relevant for those suffering from Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly seen in patients with heart failure.1,2,3 CSA/CSR is thought to affect up to 50%4,5,6 of patients with chronic heart failure and has been linked to increased mortality and morbidity in this patient population.7 The use of PaceWaveTM MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF, the world’s largest randomised trial in this field.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
